Ciliobrevin D
目录号 : GC39359
Ciliobrevin D是一种动力蛋白ATP酶活性抑制剂,可阻止马达蛋白的动力循环活动。
Cas No.:1370554-01-0
Sample solution is provided at 25 µL, 10mM.
Ciliobrevin D is an inhibitor of dynein ATPase activity, preventing the cycling activity of the motor protein[1]. Ciliobrevin D has been used to investigate dynein's role in axonal transport and in the targeting of membrane proteins and organelles[2][3][5]. Ciliobrevin D can also interfere with Hedgehog signaling and primary cilia formation[4].
In vitro, chicken dorsal root ganglion (DRG) neurons were treated with Ciliobrevin D (20μM) for 45min prevented both retrograde and anterograde movement of mitochondria. The percentage of motile lysosomes was reduced. DRG cultures were incubated in 20μM Ciliobrevin D for 60 minutes also reversibly inhibits axon extension[2]. T-ALL cells MOLT3 were pre-treated with Ciliobrevin D (20µM) for 24h and then with vehicle or pan-HDAC inhibitor Trichostatin A (TSA) (0.5µM) for 16h. TSA treatment reduced Notch3 surface levels and increased accumulation of Notch3 protein in the lysosomal compartment. Surface Notch3 levels were rescued by inhibition of dynein with Ciliobrevin D[3]. Human retinal pigment epithelial (hTERT RPE-1) cells were treated with either 50μM Ciliobrevin D, 10nM MI-181, 100nM MI-181, 50μM Ciliobrevin D + 10nM MI-181, or 50μM Ciliobrevin D + 100nM MI-181 for 24h after serum withdrawal. Ciliobrevin D treatment alone led to a marked decrease in the average length of cilia and the percentage of ciliated cells. The cilia length defects and decrease in percent ciliation observed in Ciliobrevin D treated cells were rescued to near control levels when cells were cotreated with MI-181[4].
In vivo, 5.7μL of 90μM Ciliobrevin D was stereotaxically injected into cerebral lateral ventricle of C57BL/6 mice 45min before adeno-associated virus (AAV)-9 variant, AAV.CAP-B10, administration. Ciliobrevin D restrained AAV.CAP-B10 transduction in the hippocampus[5]. Ciliobrevin D was used at 15μM per testis (assuming a testis volume of ~1.6ml at 1.6g) on adult male Sprague-Dawley rats. The needle was inserted from the apical to the basal end of the testis vertically. Ciliobrevin D treatment induced defects in spermatogenesis by leading to significant disorganization of the F-actin network and compromising the blood-testis barrier integrity[6].
References:
[1] See S K, Hoogendoorn S, Chung A H, et al. Cytoplasmic Dynein Antagonists with Improved Potency and Isoform Selectivity. ACS Chem Biol. 2016 Jan 15;11(1):53-60.
[2] Sainath R, Gallo G. The dynein inhibitor Ciliobrevin D inhibits the bidirectional transport of organelles along sensory axons and impairs NGF-mediated regulation of growth cones and axon branches.Dev Neurobiol. 2015 Jul;75(7):757-77.
[3] Pinazza M, Ghisi M, Minuzzo S, et al. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene. 2018 Jul;37(28):3839-3851.
[4] Gholkar A A, Gimeno T V, Edgemon J E, et al. MI-181 Modulates Cilia Length and Restores Cilia Length in Cells with Defective Shortened Cilia. ACS Chem Biol. 2024 Aug 16;19(8):1733-1742.
[5] Wang J C, Ding S H, He Z H,et al. Dynein-regulated brain transduction of AAV.CAP-B10 via cerebral lateral ventricle enhances hippocampal function after traumatic brain injury through Ngf gene delivery in mice. Exp Neurol. 2025 May 13:391:115285.
[6] Wen Q, Tang E I, Lui W Y, et al. Dynein 1 supports spermatid transport and spermiation during spermatogenesis in the rat testis. Am J Physiol Endocrinol Metab. 2018 Nov 1;315(5):E924-E948.
Ciliobrevin D是一种动力蛋白ATP酶活性抑制剂,可阻止马达蛋白的动力循环活动[1]。Ciliobrevin D已被用于研究动力蛋白在轴突运输以及膜蛋白和细胞器靶向中的作用[2][3][5]。Ciliobrevin D还可干扰Hedgehog信号通路和原发性纤毛的形成[4]。
体外实验中,鸡背根神经节(DRG)神经元经20μM Ciliobrevin D处理45min后,线粒体的顺行和逆行运动均被抑制,运动性溶酶体的百分比也降低。DRG培养物在20μM Ciliobrevin D中孵育60min,可以可逆性地抑制轴突延伸[2]。T-ALL细胞MOLT3先用20μM Ciliobrevin D预处理24h,再用载体或泛HDAC抑制剂三氟司他(TSA)(0.5μM)处理16h。TSA处理降低了Notch3的表面水平,并增加了Notch3蛋白在溶酶体中的积累。通过Ciliobrevin D抑制动力蛋白可恢复Notch3的表面水平[3]。人视网膜色素上皮(hTERT RPE-1)细胞在血清撤除后,分别用50μM Ciliobrevin D、10nM MI-181、100nM MI-181、50μM Ciliobrevin D+10nM MI-181或50μM Ciliobrevin D+100nM MI-181处理24h。单独使用Ciliobrevin D处理会导致纤毛平均长度明显缩短,纤毛细胞百分比降低。Ciliobrevin D处理细胞中观察到的纤毛长度缺陷和纤毛百分比下降,当细胞与MI-181联合处理时,可恢复至接近对照水平[4]。
体内实验中,将5.7μL的90μM Ciliobrevin D立体定向注射到C57BL/6小鼠脑侧脑室,于腺相关病毒(AAV)-9变体AAV.CAP-B10给药前45min进行。Ciliobrevin D限制了AAV.CAP-B10在海马区的转导[5]。在成年雄性Sprague-Dawley大鼠上,按每睾丸15μM Ciliobrevin D(假设睾丸体积约为1.6ml,重1.6g)进行处理,将针从睾丸的顶端垂直插入到底端。Ciliobrevin D处理导致精子发生缺陷,表现为F-肌动蛋白网络显著紊乱,破坏了血-睾屏障的完整性[6]。
Cell experiment [1]: | |
Cell lines | T-ALL cells MOLT3 |
Preparation Method | MOLT3 were pre-treated with Ciliobrevin D (20µM) for 24h and then with vehicle or pan-HDAC inhibitor Trichostatin A (TSA) (0.5µM) for 16h. |
Reaction Conditions | 20µM; 24h |
Applications | Ciliobrevin D rescued surface Notch3 levels reducing by TSA treatment via inhibition of dynein. |
Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | 5.7μL of 90μM Ciliobrevin D was stereotaxically injected into cerebral lateral ventricle of C57BL/6 mice 45min before adeno-associated virus (AAV)-9 variant, AAV.CAP-B10, administration. |
Dosage form | 90μM, 5.7μL/mice; stereotaxically injected into cerebral lateral ventricle; once |
Applications | Ciliobrevin D restrained AAV.CAP-B10 transduction in the hippocampus. |
References: |
Cas No. | 1370554-01-0 | SDF | |
Canonical SMILES | O=C(C1=C(C=C(Cl)C=C1)Cl)/C(C#N)=C(N2)/NC3=CC(Cl)=CC=C3C2=O | ||
分子式 | C17H8Cl3N3O2 | 分子量 | 392.62 |
溶解度 | DMSO: 5 mg/mL (12.73 mM; ultrasonic and warming and heat to 80°C) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.547 mL | 12.735 mL | 25.4699 mL |
5 mM | 0.5094 mL | 2.547 mL | 5.094 mL |
10 mM | 0.2547 mL | 1.2735 mL | 2.547 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet